Simon S. Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Simon S. Gao has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
- Yali Jia
Oregon Health and Science University
26 shared publications David Huang
Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA
15 shared publications- David Huang
Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland, OR, USA
10 shared publications - John S. Oghalai
Department of Otolaryngology-Head and Neck Surgery, University of Southern California, Los Angeles, California, USA
10 shared publications - Thomas S. Hwang
Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA
9 shared publications Liang Liu
Casey Eye Institute, Oregon Health & Science University, Portland, Oregon
8 shared publications
Latest Publications
- Open Access
- 14 March 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 275, 14-26
Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration
- 14 March 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 275, 14-26
Open AccessPhase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Open Access
- 23 October 2024
- Published by Elsevier in Ophthalmology Science
- Vol. 5 (2) , 100635
Deep Learning to Predict the Future Growth of Geographic Atrophy from Fundus Autofluorescence
- 23 October 2024
- Published by Elsevier in Ophthalmology Science
- Vol. 5 (2) , 100635
Open AccessDeep Learning to Predict the Future Growth of Geographic Atrophy from Fundus Autofluorescence
- 1 October 2023
- Published by Springer Nature
- p. 477-485
Weakly Supervised Lesion Localization of Nascent Geographic Atrophy in Age-Related Macular Degeneration
- 1 October 2023
- Published by Springer Nature
- p. 477-485
Weakly Supervised Lesion Localization of Nascent Geographic Atrophy in Age-Related Macular Degeneration
- Open Access
- 12 June 2023
- Published by Elsevier in Ophthalmology Science
- Vol. 4 (1) , 100351
Macular Sensitivity Endpoints in Geographic Atrophy
- 12 June 2023
- Published by Elsevier in Ophthalmology Science
- Vol. 4 (1) , 100351
Open AccessMacular Sensitivity Endpoints in Geographic Atrophy
- Open Access
- 20 April 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (4) , e0280484
Rare CIDEC coding variants enriched in age-related macular degeneration patients with small low-luminance deficit cause lipid droplet and fat storage defects
Background: The basis of Age-related macular degeneration (AMD) genetic risk has been well documented; however, few studies have looked at genetic biomarkers of disease progression or treatment response within advanced AMD patients. Here we report the first genome-wide analysis of genetic determinants of low-luminance vision deficit (LLD), which is seen as predictive of visual acuity loss and anti-VEGF treatment response in neovascular AMD patients. Methods: AMD patients were separated into small- and large-LLD groups for comparison and whole genome sequencing was performed. Genetic determinants of LLD were assessed by common and rare variant genetic analysis. Follow-up functional analysis of rare coding variants identified by the burden test was then performed in vitro. Results: We identified four coding variants in the CIDEC gene. These rare variants were only present in patients with a small LLD, which has been previously shown to indicate better prognosis and better anti-VEGF treatment response. Our in vitro functional characterization of these CIDEC alleles revealed that all decrease the binding affinity between CIDEC and the lipid droplet fusion effectors PLIN1, RAB8A and AS160. The rare CIDEC alleles all cause a hypomorphic defect in lipid droplet fusion and enlargement, resulting in a decreased fat storage capability in adipocytes. Conclusions: As we did not detect CIDEC expression in the ocular tissue affected by AMD, our results suggest that the CIDEC variants do not play a direct role in the eye and influence low-luminance vision deficit via an indirect and systemic effect related to fat storage capacity.
- 20 April 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (4) , e0280484
Open AccessRare CIDEC coding variants enriched in age-related macular degeneration patients with small low-luminance deficit cause lipid droplet and fat storage defects
Background: The basis of Age-related macular degeneration (AMD) genetic risk has been well documented; however, few studies have looked at genetic biomarkers of disease progression or treatment response within advanced AMD patients. Here we report the first genome-wide analysis of genetic determinants of low-luminance vision deficit (LLD), which is seen as predictive of visual acuity loss and anti-VEGF treatment response in neovascular AMD patients. Methods: AMD patients were separated into small- and large-LLD groups for comparison and whole genome sequencing was performed. Genetic determinants of LLD were assessed by common and rare variant genetic analysis. Follow-up functional analysis of rare coding variants identified by the burden test was then performed in vitro. Results: We identified four coding variants in the CIDEC gene. These rare variants were only present in patients with a small LLD, which has been previously shown to indicate better prognosis and better anti-VEGF treatment response. Our in vitro functional characterization of these CIDEC alleles revealed that all decrease the binding affinity between CIDEC and the lipid droplet fusion effectors PLIN1, RAB8A and AS160. The rare CIDEC alleles all cause a hypomorphic defect in lipid droplet fusion and enlargement, resulting in a decreased fat storage capability in adipocytes. Conclusions: As we did not detect CIDEC expression in the ocular tissue affected by AMD, our results suggest that the CIDEC variants do not play a direct role in the eye and influence low-luminance vision deficit via an indirect and systemic effect related to fat storage capacity.
- Top Cited PapersOpen Access
- 23 February 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (4)
A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment
Despite the development of effective therapies, a substantial proportion of asthmatics continue to have uncontrolled symptoms, airflow limitation, and exacerbations. Transient receptor potential cation channel member A1 (TRPA1) agonists are elevated in human asthmatic airways, and in rodents, TRPA1 is involved in the induction of airway inflammation and hyperreactivity. Here, the discovery and early clinical development of GDC-0334, a highly potent, selective, and orally bioavailable TRPA1 antagonist, is described. GDC-0334 inhibited TRPA1 function on airway smooth muscle and sensory neurons, decreasing edema, dermal blood flow (DBF), cough, and allergic airway inflammation in several preclinical species. In a healthy volunteer Phase 1 study, treatment with GDC-0334 reduced TRPA1 agonist-induced DBF, pain, and itch, demonstrating GDC-0334 target engagement in humans. These data provide therapeutic rationale for evaluating TRPA1 inhibition as a clinical therapy for asthma.
- 23 February 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (4)
Top Cited PapersOpen AccessA TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment
Despite the development of effective therapies, a substantial proportion of asthmatics continue to have uncontrolled symptoms, airflow limitation, and exacerbations. Transient receptor potential cation channel member A1 (TRPA1) agonists are elevated in human asthmatic airways, and in rodents, TRPA1 is involved in the induction of airway inflammation and hyperreactivity. Here, the discovery and early clinical development of GDC-0334, a highly potent, selective, and orally bioavailable TRPA1 antagonist, is described. GDC-0334 inhibited TRPA1 function on airway smooth muscle and sensory neurons, decreasing edema, dermal blood flow (DBF), cough, and allergic airway inflammation in several preclinical species. In a healthy volunteer Phase 1 study, treatment with GDC-0334 reduced TRPA1 agonist-induced DBF, pain, and itch, demonstrating GDC-0334 target engagement in humans. These data provide therapeutic rationale for evaluating TRPA1 inhibition as a clinical therapy for asthma.
- 2 June 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (1) , 129-139
Development of AITC‐induced dermal blood flow as a translational in vivo biomarker of TRPA1 activity in human and rodent skin
Background and Purpose: Develop a translational assay of Transient Receptor Potential Ankyrin 1 (TRPA1) activity for use as a preclinical and clinical biomarker. Experimental Approach: Allyl isothiocyanate (AITC), capsaicin or citric acid were applied to ears of wildtype and Trpa1 ‐knock out ( Trpa1 KO ) rats, and changes in dermal blood flow (DBF) were measured by laser speckle contrast imaging. In humans, the DBF, pain and itch responses to 5‐20% AITC applied to the forearm were measured and safety was evaluated. Reproducibility of the DBF, pain and itch responses to topically applied 10% and 15% AITC were assessed at two visits separated by 13‐15 days. DBF changes were summarized at 5‐minute intervals as areas under the curve (AUC) and maxima. Intraclass correlation coefficient (ICC) was calculated to assess arm‐arm and period‐period reproducibility. Key Results: AITC‐ and citric acid‐induced DBF were significantly reduced in Trpa1 KO rats compared to wildtype (90 ± 2% and 65 ± 11% reduction, respectively), whereas capsaicin response did not differ. In humans, each AITC concentration significantly increased DBF compared to vehicle with the maximal increase occurring 5 minutes post application. Ten percent and 15% AITC were selected as safe and effective stimuli. AUC from 0 to 5 minutes was the most reproducible metric of AITC‐induced DBF across arms (ICC = 0.92) and periods (ICC = 0.85). Subject‐reported pain was more reproducible than itch across visits (ICC = 0.76 vs 0.17, respectively). Conclusion and Implications: AITC‐induced DBF is a suitable target engagement biomarker of TRPA1 activity for preclinical and clinical studies of TRPA1 antagonists.
- 2 June 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (1) , 129-139
Development of AITC‐induced dermal blood flow as a translational in vivo biomarker of TRPA1 activity in human and rodent skin
Background and Purpose: Develop a translational assay of Transient Receptor Potential Ankyrin 1 (TRPA1) activity for use as a preclinical and clinical biomarker. Experimental Approach: Allyl isothiocyanate (AITC), capsaicin or citric acid were applied to ears of wildtype and Trpa1 ‐knock out ( Trpa1 KO ) rats, and changes in dermal blood flow (DBF) were measured by laser speckle contrast imaging. In humans, the DBF, pain and itch responses to 5‐20% AITC applied to the forearm were measured and safety was evaluated. Reproducibility of the DBF, pain and itch responses to topically applied 10% and 15% AITC were assessed at two visits separated by 13‐15 days. DBF changes were summarized at 5‐minute intervals as areas under the curve (AUC) and maxima. Intraclass correlation coefficient (ICC) was calculated to assess arm‐arm and period‐period reproducibility. Key Results: AITC‐ and citric acid‐induced DBF were significantly reduced in Trpa1 KO rats compared to wildtype (90 ± 2% and 65 ± 11% reduction, respectively), whereas capsaicin response did not differ. In humans, each AITC concentration significantly increased DBF compared to vehicle with the maximal increase occurring 5 minutes post application. Ten percent and 15% AITC were selected as safe and effective stimuli. AUC from 0 to 5 minutes was the most reproducible metric of AITC‐induced DBF across arms (ICC = 0.92) and periods (ICC = 0.85). Subject‐reported pain was more reproducible than itch across visits (ICC = 0.76 vs 0.17, respectively). Conclusion and Implications: AITC‐induced DBF is a suitable target engagement biomarker of TRPA1 activity for preclinical and clinical studies of TRPA1 antagonists.
- 1 October 2019
- Published by Elsevier in Ophthalmology Retina
- Vol. 3 (10) , 835-842
Signal Strength Reduction Effects in OCT Angiography
- 1 October 2019
- Published by Elsevier in Ophthalmology Retina
- Vol. 3 (10) , 835-842
Signal Strength Reduction Effects in OCT Angiography
- 2 March 2018
- Published by Elsevier in Ophthalmology Retina
- Vol. 2 (9) , 931-941
Quantitative Evaluation of Choroidal Neovascularization under Pro Re Nata Anti–Vascular Endothelial Growth Factor Therapy with OCT Angiography
- 2 March 2018
- Published by Elsevier in Ophthalmology Retina
- Vol. 2 (9) , 931-941
Quantitative Evaluation of Choroidal Neovascularization under Pro Re Nata Anti–Vascular Endothelial Growth Factor Therapy with OCT Angiography